Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Pharmacokinetics of zidovudine in infants: a population analysis across studies.

Mirochnick M, Capparelli E, Connor J.

Clin Pharmacol Ther. 1999 Jul;66(1):16-24.

PMID:
10430105
2.

Pharmacokinetics and tolerance of zidovudine in preterm infants.

Capparelli EV, Mirochnick M, Dankner WM, Blanchard S, Mofenson L, McSherry GD, Gay H, Ciupak G, Smith B, Connor JD; Pediatric AIDS Clinical Trials Group 331 Investigators.

J Pediatr. 2003 Jan;142(1):47-52.

PMID:
12520254
3.

Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis.

Anderson BJ, van Lingen RA, Hansen TG, Lin YC, Holford NH.

Anesthesiology. 2002 Jun;96(6):1336-45.

PMID:
12170045
4.

Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.

Kovacs A, Cowles MK, Britto P, Capparelli E, Fowler MG, Moye J, McIntosh K, Rathore MH, Pitt J, Husson RN.

Pediatr Infect Dis J. 2005 Jun;24(6):503-9.

PMID:
15933559
5.

Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus.

Boucher FD, Modlin JF, Weller S, Ruff A, Mirochnick M, Pelton S, Wilfert C, McKinney R Jr, Crain MJ, Elkins MM, et al.

J Pediatr. 1993 Jan;122(1):137-44.

PMID:
8419601
6.

Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study.

Nielsen EI, Sandström M, Honoré PH, Ewald U, Friberg LE.

Clin Pharmacokinet. 2009;48(4):253-63. doi: 10.2165/00003088-200948040-00003.

PMID:
19492870
7.

The effect of postnatal age on gentamicin pharmacokinetics in neonates.

Knight JA, Davis EM, Manouilov K, Hoie EB.

Pharmacotherapy. 2003 Aug;23(8):992-6.

PMID:
12921246
8.

HIV infection and zidovudine use in childbearing women.

Sia J, Paul S, Martin RM, Cross H.

Pediatrics. 2004 Dec;114(6):e707-12. Epub 2004 Nov 15.

PMID:
15545619
9.

Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children.

Capparelli EV, Englund JA, Connor JD, Spector SA, McKinney RE, Palumbo P, Baker CJ.

J Clin Pharmacol. 2003 Feb;43(2):133-40.

PMID:
12616665
10.

Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.

Vanhove GF, Kastrissios H, Gries JM, Verotta D, Park K, Collier AC, Squires K, Sheiner LB, Blaschke TF.

Antimicrob Agents Chemother. 1997 Nov;41(11):2428-32.

11.

Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis.

Anderson BJ, Pons G, Autret-Leca E, Allegaert K, Boccard E.

Paediatr Anaesth. 2005 Apr;15(4):282-92.

PMID:
15787918
12.

The influences of renal function and maturation on vancomycin elimination in newborns and infants.

Capparelli EV, Lane JR, Romanowski GL, McFeely EJ, Murray W, Sousa P, Kildoo C, Connor JD.

J Clin Pharmacol. 2001 Sep;41(9):927-34.

PMID:
11549096
13.

Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment.

Shapiro RL, Holland DT, Capparelli E, Lockman S, Thior I, Wester C, Stevens L, Peter T, Essex M, Connor JD, Mirochnick M.

J Infect Dis. 2005 Sep 1;192(5):720-7. Epub 2005 Jul 27.

PMID:
16088821
14.

Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.

Suksomboon N, Poolsup N, Ket-Aim S.

J Clin Pharm Ther. 2007 Jun;32(3):293-311. Review.

PMID:
17489882
15.

Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.

Fletcher CV, Yogev R, Nachman SA, Wiznia A, Pelton S, McIntosh K, Stanley K.

Pharmacotherapy. 2004 Apr;24(4):453-9.

PMID:
15098798
16.

Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team.

Lambert JS, Watts DH, Mofenson L, Stiehm ER, Harris DR, Bethel J, Whitehouse J, Jimenez E, Gandia J, Scott G, O'Sullivan MJ, Kovacs A, Stek A, Shearer WT, Hammill H, van Dyke R, Maupin R, Silio M, Fowler MG.

AIDS. 2000 Jul 7;14(10):1389-99.

PMID:
10930154
17.

Population pharmacokinetics of gentamicin in premature newborns.

García B, Barcia E, Pérez F, Molina IT.

J Antimicrob Chemother. 2006 Aug;58(2):372-9. Epub 2006 Jun 16.

PMID:
16782742
18.

Consequences of delayed surgical closure of patent ductus arteriosus in very premature infants.

Jaillard S, Larrue B, Rakza T, Magnenant E, Warembourg H, Storme L.

Ann Thorac Surg. 2006 Jan;81(1):231-4.

PMID:
16368371
19.
20.

Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.

Morse GD, Reichman RC, Fischl MA, Para M, Leedom J, Powderly W, Demeter LM, Resnick L, Bassiakos Y, Timpone J, Cox S, Batts D.

Antiviral Res. 2000 Jan;45(1):47-58.

PMID:
10774589

Supplemental Content

Support Center